NL-OMON36589CompletedNot Applicable
Effect of administration route on the pharmacokinetics of cobalamin in elderly - Pharmacokinetics of Cobalamin
Stichting Apotheek der Haarlemse Ziekenhuizen0 sites10 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- Cobalamin deficiency (cobalamin serum level less than 200 pmol/l)
- •- Age 65 years or over
- •- Capable of understanding the study information
- •- informed consent
Exclusion Criteria
- •- Concomitant use of nasally administered medication
- •- Chronic rhinitis
- •- Running nose
- •- Clinical relevant infection
- •- Hemodynamic Instability
- •- Short Nutritional Questionnaire Score (SNAQ) of 3 or over
- •- Use of cobalamin containing dietary supplements
- •- Severe Renal impairment i.e. MDRD less than 20 ml/min
- •- Ethical or medical reasons upon discretion of the investigators
Investigators
Similar Trials
Recruiting
Not Applicable
Het effect van de vitamine B12 toediengsvorm op het verloop van de hoeveelheid vitamine B12 in het bloed.Cobalamin deficiency(cobalamine deficientie of vitamine B12 deficientie, ouderen)NL-OMON20477Stichting Apotheek der Haarlemse Ziekenhuizen (SAHZ)10
Suspended
Phase 4
Impact of injection site on buprenorphine pharmacokinetics.ACTRN12623000691640Sydney Local Health District50
Active, not recruiting
Phase 1
Metabolism and effects of naloxone given as a spray in healthy volunteers and children.Sedation after opioid administrationPharmacokinetic profile after naloxone administered intranasallyEUCTR2013-005201-31-SEKarolinska University Hospital20
Completed
Phase 1
Interactions between herbal medicines and the anticoagulant warfariDrug interactions of warfarin with herbal medicines in healthy male subjects. Relevant to Stroke prevention and people receiving warfarinStroke -Other -ACTRN12607000054415Prof Andrew McLachlan60
Active, not recruiting
Not Applicable
A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779 Injection in Patients with von Willebrand Disease Type 2B - ARC1779 for VWD-2Bvon Willebrand Disease type 2BEUCTR2008-008532-82-ATMedical University of Vienna, Dept. of Clinical Pharmacology